Oskar Hoff Email

Head Chemistry Lab . Celeris Therapeutics

Menlo Park, Kalifornien

Location

Current Roles

Employees:
24
Revenue:
$2.4M
About
Celeris Therapeutics is going to solve the R&D shortcomings as the pioneer in AI-driven PIC (proximity-inducing compounds) design using an innovative closed-loop engine (Celeris One™ platform) to develop new chemical entities (NCEs) that degrade proteins by establishing proximity to endogenous cellular mechanisms. The solutions include machine learning-driven prediction of interactions, generative design, optimization of molecular properties, and automation of laboratory devices. CelerisTx's drug pipeline is focused on CNS and oncology, targeting unmet medical needs. We also co-develop therapeutics with pharmaceutical and biotech companies. CelerisTx has so far attracted a total of EUR 18 million in committed capital from venture capital funds, which include EIC Fund, Pace Ventures Enigma, i&i biotech, Apex Ventures, R42 and longevitytech.fund. #targetedproteindegradation #degrader #ubiquitinproteasomesystem #machinelearning #CelerisOne #proximityinducingcompounds #PICs
Celeris Therapeutics Address
585 Glenwood Ave
Menlo Park, Kalifornien
Celeris Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.